Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.
The European Commission has approved Novartis‘s Mayzent (siponimod) as the first oral treatment for adults with active secondary progressive multiple sclerosis (SPMS). Active SPMS is defined by the presence of evident relapses or the ... Read more
The high cost of disease-modifying therapies (DMTs) for multiple sclerosis (MS), and the challenging process of insurance approval, lead to treatment gaps or alterations, increased symptoms, and sacrifices in ... Read more
Recovering well after a first relapse and starting a disease-modifying therapy (DMT) immediately afterward considerably increases the likelihood of slowing progression in multiple sclerosis (MS), a study suggests. Its findings ... Read more
A common mutation in the fat-mass obesity (FTO) gene is associated with obesity and increased disability in people with multiple sclerosis (MS), according to a Kuwaiti study. The data, which ... Read more
Probiotics show potential to prevent and delay the development of multiple sclerosis (MS) by changing immune and inflammatory responses, according to a review study. Data further support the link ... Read more
Pregnancy does not lead to long-term changes in the disease course of multiple sclerosis (MS), new research suggests. This work, which emphasizes the importance of careful data analysis, supports studies disputing ... Read more
Long-term treatment with interferon beta (IFN-beta) corrects the defective immune balance characteristic of people with relapsing-remitting multiple sclerosis (RRMS), a study has found. The study also identified more than 200 genes ... Read more
Physical symptoms and poorer coping mechanisms are major risk factors for unemployment in younger and older people with multiple sclerosis (MS), while psychological problems have the greatest impact in ... Read more
Higher intellectual ability and physical activity during childhood and adolescence may help protect against the development of cognitive impairment in people with multiple sclerosis (MS), an Italian study suggests. ... Read more
Endothelin-1 (ET-1) — a molecule with potent blood vessel-narrowing (vasoconstrictive) properties — may be used as a biomarker of severity for optic neuritis in people with multiple sclerosis (MS), ... Read more
Blocking production of the low-density lipoprotein receptor-related protein 1 (LRP1) — involved in inflammatory and immune responses — specifically in myelin repair cells halts neuroinflammation and promotes myelin repair, a ... Read more
Brain inflammation in multiple sclerosis (MS) hijacks immature myelin repair cells, not only preventing myelin restoration but also promoting sustained inflammation and immune attacks against myelin, a preclinical study shows.
The ... Read more
Persistent fatigue in people with multiple sclerosis (MS) is associated with damage in specific areas of the brain, regardless of depression symptoms, a study shows. The study, “Microstructural fronto-striatal ... Read more
A Phase 1 clinical trial found T20K, Cyxone’s investigational plant protein-derived treatment for multiple sclerosis (MS), to be safe and well-tolerated in healthy men, and raising the possibility that it might work ... Read more
Tysabri (natalizumab) was reported in a small retrospective study to significantly improve cognitive abilities in people with relapsing-remitting MS patients (RRMS) over two years of use. The study, “Improvement in Cognitive ... Read more
Spasticity scales may be insufficient to reflect the actual benefits of Sativex (nabiximols) treatment on spasticity symptoms in people with multiple sclerosis (MS), according to a small case series ... Read more
Tecfidera (dimethyl fumarate) and Gilenya (fingolimod) are equally effective in treating multiple sclerosis (MS), but Tecfidera shows higher rates of discontinuation, according to a real-world study. The study, “Discontinuation and comparative effectiveness ... Read more
Most patients with multiple sclerosis (MS) are satisfied with the conditions of their intravenous therapy (administered directly into the bloodstream) and are very aware of the therapy’s safety, according to ... Read more
Higher-than-usual levels of specific antibodies in the blood of patients with clinically isolated syndrome (CIS) may predict a faster progression to multiple sclerosis, an Australian study reports. The specific antibody is known ... Read more
Being treated with ozanimod consistently reduced disease activity in people with relapsing-remitting multiple sclerosis (RRMS), according to results of a two-year extension of a Phase 2 trial. These benefits were ... Read more
A large U.K. survey assessing the frequency of chickenpox and shingles in multiple sclerosis (MS) patients suggests a link between these diseases and MS, researchers report, suggesting their findings ... Read more
Sweden’s Active Biotech said its experimental therapy Laquinimod failed to meet the primary and secondary objectives of Phase 2 clinical trial evaluating the drug’s potential to treat primary progressive multiple sclerosis.
Laquinimod, also known as Nerventra or ABR-215062, ... Read more
Smoking changes a DNA-based mechanism that influences multiple sclerosis patients’ gene activity, a Swedish study confirms. Another finding was that MS appears to aggravate the harmful effects of smoking. ... Read more
A national survey in the U.S. revealed that 98% of women newly diagnosed with multiple sclerosis struggle to discuss important personal concerns with their healthcare team.
The survey was conducted ... Read more